Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated September 16, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries. The filing specifically details transactions executed under a programme initiated on August 7, 2024, which is part of a broader authorization to repurchase up to DKK 20 billion over a 12-month period starting February 6, 2024.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Share Repurchase Programme Limit: Up to DKK 20 billion (12-month period from February 6, 2024).
- Specific Programme Limit (Aug 7 - Nov 4, 2024): Up to DKK 2.4 billion.
- Total Repurchased (Feb 6 - Sep 13, 2024): 12,235,249 B shares with a transaction value of DKK 10,782,912,990.
- Average Share Price (Total Period): DKK 881.30 per B share.
- Treasury Shares Held: 13,563,880 B shares (0.3% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Transaction Details
Since the last announcement on September 9, 2024, the company executed the following transactions under the August 7 programme:
| Date | Number of B Shares | Average Purchase Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| September 9, 2024 | 42,500 | 888.73 | 37,771,210 |
| September 10, 2024 | 42,500 | 877.04 | 37,274,389 |
| September 11, 2024 | 42,500 | 891.52 | 37,889,410 |
| September 12, 2024 | 42,436 | 916.48 | 38,891,633 |
| September 13, 2024 | 42,000 | 924.52 | 38,829,827 |
Accumulated transactions under the specific August 7 programme total 1,168,123 shares valued at DKK 1,055,206,940.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 20 billion limit during the 12-month period beginning February 6, 2024. The company aims to drive change to defeat serious chronic diseases, leveraging its heritage in diabetes.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard execution of the share repurchase programme in accordance with EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Important Facts for Investors to Verify
- Confirm the remaining capacity under the DKK 20 billion total repurchase authorization after the DKK 10.78 billion already spent.
- Verify the current market price of B shares relative to the recent average purchase prices (ranging from DKK 877 to DKK 924).
- Check the company's latest quarterly or annual report (Form 20-F) for operational financial metrics (revenue, profit, cash flow) which are not included in this 6-K filing.
- Monitor the timeline for the conclusion of the specific August 7 programme, which ends on November 4, 2024.